Nothing Special   »   [go: up one dir, main page]

CL2019001214A1 - Composición farmacéutica, métodos para tratamiento y sus usos. - Google Patents

Composición farmacéutica, métodos para tratamiento y sus usos.

Info

Publication number
CL2019001214A1
CL2019001214A1 CL2019001214A CL2019001214A CL2019001214A1 CL 2019001214 A1 CL2019001214 A1 CL 2019001214A1 CL 2019001214 A CL2019001214 A CL 2019001214A CL 2019001214 A CL2019001214 A CL 2019001214A CL 2019001214 A1 CL2019001214 A1 CL 2019001214A1
Authority
CL
Chile
Prior art keywords
methods
treatment
pharmaceutical composition
chronic renal
renal disease
Prior art date
Application number
CL2019001214A
Other languages
English (en)
Inventor
Hans-Juergen Woerle
Eynatten Maximilian Von
Uli Christian Broedl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019001214A1 publication Critical patent/CL2019001214A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA TRATAR O PREVENIR LA ENFERMEDAD RENAL CRÓNICA Y LA ENFERMEDAD CARDIOVASCULAR EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA, QUE COMPRENDEN ADMINISTRAR EMPAGLIFLOZINA AL PACIENTE.
CL2019001214A 2016-11-10 2019-05-02 Composición farmacéutica, métodos para tratamiento y sus usos. CL2019001214A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420062P 2016-11-10 2016-11-10
US201762514249P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
CL2019001214A1 true CL2019001214A1 (es) 2019-07-26

Family

ID=60293959

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001214A CL2019001214A1 (es) 2016-11-10 2019-05-02 Composición farmacéutica, métodos para tratamiento y sus usos.

Country Status (13)

Country Link
US (4) US20180125813A1 (es)
EP (1) EP3538107A1 (es)
JP (2) JP2019533709A (es)
KR (2) KR20190084096A (es)
CN (1) CN109922813A (es)
AU (2) AU2017357589B2 (es)
BR (1) BR112019008384A2 (es)
CA (1) CA3039745A1 (es)
CL (1) CL2019001214A1 (es)
MA (1) MA46742A (es)
MX (2) MX2019005435A (es)
PH (1) PH12019501018A1 (es)
WO (1) WO2018087132A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
HRP20220365T1 (hr) 2013-04-18 2022-05-13 Boehringer Ingelheim International Gmbh Farmaceutski pripravak, postupci za liječenje i njegove uporabe
CR20210222A (es) * 2020-07-27 2022-08-29 Astrazeneca Ab Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
MX2024007335A (es) * 2021-12-14 2024-06-26 Boehringer Ingelheim Int Inhibidores de aldosterona sintasa para tratar la enfermedad renal cronica.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
RS65252B1 (sr) 2009-02-13 2024-03-29 Boehringer Ingelheim Int Farmaceutska kompozicija koja sadrži glukopiranozil difenilmetan derivate, njihov farmaceutski dozni oblik, postupak njihovog dobijanja i njihova primena za poboljšanu glikemijsku kontrolu kod pacijenta
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2483286B1 (en) 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) * 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
HRP20220365T1 (hr) * 2013-04-18 2022-05-13 Boehringer Ingelheim International Gmbh Farmaceutski pripravak, postupci za liječenje i njegove uporabe

Also Published As

Publication number Publication date
US20200138770A1 (en) 2020-05-07
KR20230162125A (ko) 2023-11-28
CA3039745A1 (en) 2018-05-17
KR20190084096A (ko) 2019-07-15
JP2023010710A (ja) 2023-01-20
US20220288012A1 (en) 2022-09-15
WO2018087132A1 (en) 2018-05-17
US20180125813A1 (en) 2018-05-10
CN109922813A (zh) 2019-06-21
EP3538107A1 (en) 2019-09-18
AU2017357589B2 (en) 2023-05-11
BR112019008384A2 (pt) 2019-07-09
JP2019533709A (ja) 2019-11-21
MX2023000796A (es) 2023-02-27
MX2019005435A (es) 2019-07-10
PH12019501018A1 (en) 2019-12-16
AU2023203321A1 (en) 2023-06-22
AU2017357589A1 (en) 2019-04-18
MA46742A (fr) 2019-09-18
US20210228533A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
PH12018502593A1 (en) Combinations of linagliptin and metformin
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
UY35478A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA IL-1ß y/o IL-17
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112018013833A2 (pt) métodos de administração de hepcidina
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112017025553A2 (pt) composição de vacina, e kit
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
CY1118532T1 (el) Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MD4763B1 (ro) Compoziţie farmaceutică
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor